Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial.

Robin L Jones Andrew J WagnerAkira KawaiKazuo TamuraAshwin ShahirBrian Andrew Van Tine Javier Martín-BrotoPatrick M PetersonJennifer WrightWilliam D Tap

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Although follow-up was short, these results suggest doxorubicin can be administered at high cumulative doses (>450 mg/m2), with a low rate of cardiotoxicities, in the context of dexrazoxane coadministration.See related commentary by Benjamin and Minotti, p. 3809.

Keyphrases

phase iii
open label
clinical trial
drug delivery
cancer therapy
double blind
phase ii
placebo controlled
randomized controlled trial
newly diagnosed
study protocol